Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in …

Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in …
BASEL, Switzerland & CAMBRIDGE, Mass.—-Roche and Biogen Idec today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis .
Read more on Business Wire via Yahoo! Finance

Ligand receives US$ 6.5 mn from Roche for progression of RG7348 into phase-I trial in treatment of HCV infection

Ligand receives US$ 6.5 mn from Roche for progression of RG7348 into phase-I trial in treatment of HCV infection
Ligand Pharmaceuticals Incorporated announced that it earned a US$ 6.5 million payment from Roche as a result of Roche progressing RG7348 into a phase-I clinical trial for the treatment of hepatitis C viral (HCV) infection.
Read more on [...]

Ligand Earns $6.5 Million Milestone Payment from Roche

Ligand Earns $6.5 Million Milestone Payment from Roche
SAN DIEGO—-Ligand Pharmaceuticals Incorporated today announced that it earned a $6.5 million payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral infection.
Read more on Business Wire via Yahoo! Finance